Implication of plasma intermedin levels in patients who underwent first-time diagnostic coronary angiography: a single centre, cross-sectional study

BMC Cardiovascular Disorders

Omer Goktekin¹  Ercan Erdogan¹  Parviz Jafarov¹  Muharrem Nasifov¹  Emin Asoglu¹  Emrah Sevgili¹  Sitki Kucukbuzcu¹  Ziya Ismailoglu¹  Ahmet Bacaksiz¹  Aylin Hatice Yamac¹ 

[1] Faculty of Medicine, Department of Cardiology, BezmiÂlem Foundation University, Adnan Menderes Avenue, Vatan Street, 34093 Fatih, Istanbul, Turkey

关键词: Diagnostic coronary angiography;    Coronary artery disease;    Intermedin;   

Others  :  1088411
DOI  :  10.1186/1471-2261-14-182

 received in 2014-07-24, accepted in 2014-11-26,  发布年份 2014

【 摘 要 】

Background

Intermedin (IMD) is involved in the prevention of atherosclerotic plaque progression, possessing cardioprotective effects from hypertrophy, fibrosis and ischemia-reperfusion injury. Elevated plasma IMD levels have been demonstrated in patients with acute coronary syndromes. No human study has examined the role of IMD in stable patients who underwent diagnostic coronary angiography with suspicion of coronary artery disease (CAD). Thus we investigated the role of IMD as a biomarker to discriminate patients with CAD and predict those with severe disease who require early and intensive therapeutic intervention before presenting with acute coronary syndrome.

Methods

Eligible two hundred and thirty-eight consecutive patients (123 males, mean age 58.4 ± 10.0 years) who underwent first-time diagnostic coronary angiography were included in this study. Plasma concentrations of IMD were measured from arterial blood samples by the enzyme-linked immunosorbent assay. Patients were divided into three groups according to the presence and degree of CAD, consisting of 48 patients with normal coronary anatomy (Group 1), 111 patients with < 50% coronary stenosis (Group 2), and 79 patients with ≥ 50% stenosis in at least one of the major coronary arteries (group 3). The severity and extent of CAD was evaluated by calculations of the vessel, Gensini, and SYNTAX scores.

Results

Circulating plasma IMD levels in patients with CAD were significantly higher than those in patients without CAD (157.7 ± 9.6, 134.8 ± 11.9, and 117.6 ± 7.9 pg/mL in groups 3, 2 and 1 respectively; p < 0.001). Besides, plasma IMD levels were correlated with Gensini and SYNTAX scores (r_s = 0.742, and r_s = 0.296, respectively; p < 0.05). The presence of ≥50% coronary artery stenosis could be predicted if a cut-off value of 147.7 pg/mL for plasma IMD was used with 88.6% sensitivity and 88.7% specificity. Moreover, a plasma IMD level of <126.6 pg/mL could discriminate a patient with normal coronary arteries from patients with angiographically proven CAD with a sensitivity and specificity of 84.7%, and 83.3% respectively.

Conclusions

We demonstrated that IMD might be used as a biomarker to predict CAD and its severity in patients who underwent first time diagnostic coronary angiography.

【 授权许可】

   
2014 Yamac et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Nürnberger J, Kribben A, Philipp T, Erbel R: Arterial compliance (stiffness) as a marker of subclinical atherosclerosis. Herz 2007, 32(5):379-386.
• [2]Hansson GK, Robertson AK, Söderberg-Nauclér C: Inflammation and atherosclerosis. Annu Rev Pathol 2006, 1:297-329.
• [3]Giannotti G, Landmesser U: Endothelial dysfunction as an early sign of atherosclerosis. Herz 2007, 32(7):568-572.
• [4]Libby P, Ridker PM, Hansson GK: Leducq transatlantic network on atherothrombosis: inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54(23):2129-2138.
• [5]Pan CS, Yang JH, Cai DY, Zhao J, Gerns H, Yang J, Chang JK, Tang CS, Qi YF: Cardiovascular effects of newly discovered peptide intermedin/adrenomedullin 2. Peptides 2005, 26(9):1640-1646.
• [6]Bell D, McDermott BJ: Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems. Br J Pharmacol 2008, 153(Suppl 1):S247-S262.
• [7]Yang X, Zhang H, Jia Y, Ni L, Li G, Xue L, Jiang Y: Effects of intermedin1-53 on myocardial fibrosis. Acta Biochim Biophys Sin (Shanghai) 2013, 45(2):141-148.
• [8]Zhao L, Peng DQ, Zhang J, Song JQ, Teng X, Yu YR, Tang CS, Qi YF: Extracellular signal-regulated kinase 1/2 activation is involved in intermedin1-53 attenuating myocardial oxidative stress injury induced by ischemia/reperfusion. Peptides 2012, 33(2):329-335.
• [9]Zhang X, Gu L, Chen X, Wang S, Deng X, Liu K, Lv Z, Yang R, He S, Peng Y, Huang D, Jiang W, Wu K: Intermedin ameliorates atherosclerosis in ApoE null mice by modifying lipid profiles. Peptides 2012, 37(2):189-193.
• [10]Qin YW, Teng X, He JQ, Du J, Tang CS, Qi YF: Increased plasma levels of intermedin and brain natriuretic peptide associated with severity of coronary stenosis in acute coronary syndrome. Peptides 2013, 42:84-88.
• [11]Lv Z, Wu K, Chen X, Zhang X, Hong B: Plasma intermedin levels in patients with acute myocardial infarction. Peptides 2013, 43:121-125.
• [12]Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983, 51(3):606.
• [13]Sullivan DR, Marwick TH, Freedman SB: A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990, 119(6):1262-1267.
• [14]Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW: The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005, 1(2):219-227.
• [15]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(6):499-502.
• [16]Roh J, Chang CL, Bhalla A, Klein C, Hsu SY: Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 2004, 279(8):7264-7274.
• [17]Hinson JP, Kapas S, Smith DM: Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000, 21(2):138-167.
• [18]Bell D, Zhao Y, McCoy FP, Devine A, McDermott BJ: Expression of the counter-regulatory peptide intermedin is augmented in the presence of oxidative stress in hypertrophied cardiomyocytes. Cell Physiol Biochem 2008, 21(5–6):409-420.
• [19]Hirose T, Totsune K, Mori N, Morimoto R, Hashimoto M, Nakashige Y, Metoki H, Asayama K, Kikuya M, Ohkubo T, Hashimoto J, Sasano H, Kohzuki M, Takahashi K, Imai Y: Increased expression of adrenomedullin 2/intermedin in rat hearts with congestive heart failure. Eur J Heart Fail 2008, 10(9):840-849.
• [20]Bell D, Campbell M, Ferguson M, Sayers L, Donaghy L, O’Regan A, Jewhurst V, Harbinson M: AM(1)-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury. J Physiol 2012, 590(Pt 5):1181-1197.
• [21]Du QX, Yue W, Wang YY: Effect and mechanism of intermedin in acute rat cardiac ischemic injury. Fa yi xue za zhi 2011, 27(3):164-168.
• [22]Teng X, Song J, Zhang G, Cai Y, Yuan F, Du J, Tang C, Qi Y: Inhibition of endoplasmic reticulum stress by intermedin(1–53) protects against myocardial injury through a PI3 kinase-Akt signaling pathway. J Mol Med (Berl) 2011, 89(12):1195-1205.
• [23]Song JQ, Teng X, Cai Y, Tang CS, Qi YF: Activation of Akt/GSK-3beta signaling pathway is involved in intermedin(1–53) protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis 2009, 14(11):1299-1307.